Zentalis Pharmaceuticals (ZNTL) Projected to Post Earnings on Friday

Key Points

• Zentalis Pharmaceuticals (NASDAQ:ZNTL) is scheduled to announce its Q2 2025 earnings on August 8th, with analysts expecting a loss of ($0.56) per share.
• The stock has a current price of $1.38, with a fifty-two week low of $1.01 and a high of $5.44, reflecting a market capitalization of $99.29 million.
• Recent analyst ratings include a "neutral" rating from Wedbush with a $4.00 price target and a "buy" rating from HC Wainwright with a $10.00 target, contributing to a consensus rating of "Moderate Buy" and an average price target of $8.37.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Friday, August 8th. Analysts expect Zentalis Pharmaceuticals to post earnings of ($0.56) per share for the quarter.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, hitting analysts' consensus estimates of ($0.67). On average, analysts expect Zentalis Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ:ZNTL traded down $0.04 during midday trading on Friday, reaching $1.34. 416,410 shares of the company's stock were exchanged, compared to its average volume of 751,526. The company's 50 day simple moving average is $1.36 and its two-hundred day simple moving average is $1.60. The firm has a market capitalization of $96.41 million, a PE ratio of -0.43 and a beta of 1.71. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $5.44.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Wedbush reaffirmed a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $8.37.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

An institutional investor recently raised its position in Zentalis Pharmaceuticals stock. Millennium Management LLC raised its stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 220.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,069,514 shares of the company's stock after acquiring an additional 2,111,951 shares during the quarter. Millennium Management LLC owned about 4.27% of Zentalis Pharmaceuticals worth $4,881,000 as of its most recent filing with the Securities and Exchange Commission.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.